Selective depletion of metastatic stem cells as therapy for human colorectal cancer

Area of Science:

• Oncology
• Nanomedicine
• Cancer Biology

Background:

• Metastatic stem cells (MetSCs) drive cancer dissemination.
• Colorectal cancer (CRC) cells overexpressing CXCR4 are key to metastasis.
• Targeting MetSCs offers a strategy to block cancer spread.

Purpose of the Study:

• To assess the antimetastatic activity of a novel nanoconjugate, T22-GFP-H6-FdU.
• To determine if T22-GFP-H6-FdU can selectively deliver Floxuridine to CXCR4+ cancer cells.
• To evaluate the efficacy of this targeted delivery in blocking CRC metastasis and re-initiation.

Main Methods:

• Development of a nanoconjugate (T22-GFP-H6-FdU) for targeted Floxuridine delivery.
• Administration of the nanoconjugate intravenously in CRC cell line and patient-derived models.
• Assessment of nanoconjugate accumulation, cellular uptake, DNA damage, apoptosis, and metastatic progression.
• Comparison of nanoconjugate efficacy against free Floxuridine regarding metastasis prevention and regression.

Main Results:

• T22-GFP-H6-FdU selectively accumulated and internalized in CXCR4+ cancer cells.
• The nanoconjugate triggered DNA damage and apoptosis in target cells, reducing tumor re-initiation.
• Complete prevention of metastases occurred in 38-83% of mice; others showed reduced foci number and size.
• Established metastases showed greater regression with T22-GFP-H6-FdU than with free Floxuridine.
• Negligible distribution and toxicity were observed in normal tissues.

Conclusions:

• Targeted delivery of Floxuridine via T22-GFP-H6-FdU effectively eliminates metastatic CXCR4+ cancer cells.
• This nanoconjugate demonstrates potent antimetastatic effects, blocking dissemination and regressing established tumors.
• Metastatic stem cells (MetSCs) are validated as viable targets for clinical cancer therapy.